Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Non-Small-Cell Lung 252Breast Neoplasms 197Glioblastoma 196Lung Neoplasms 195Head and Neck Neoplasms 176Squamous Cell Carcinoma of Head and Neck 166Prostatic Neoplasms 164Lymphoma 152Rectal Neoplasms 132Central Nervous System Neoplasms 119Esophageal Neoplasms 117Leukemia 111Brain Neoplasms 100Pancreatic Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 86Esophageal Squamous Cell Carcinoma 83Lymphoma, Follicular 81Sarcoma 80Lymphoma, Large B-Cell, Diffuse 80Uterine Cervical Neoplasms 76Lymphoma, Non-Hodgkin 75Hodgkin Disease 73Neoplasms 68Burkitt Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Colorectal Neoplasms 63Glioma 61Astrocytoma 60Lymphoma, Large-Cell, Immunoblastic 58

Interventions

pembrolizumab 92Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 24Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × Radiotherapy × Clear all
NCT03486197 2024-11-20

Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma

University of Washington

Phase 2 Terminated
12 enrolled 10 charts
Genitourinary

Carcinoma, Transitional Cell

NCT05912205 2023-06-22

Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡